Articles tagged with Immunotherapy
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers identified a genetic variant associated with increased response to anti-PD-1 therapy and higher immune-related side effects in lung cancer patients. The variant, found in 15.7% of exceptional responders, may be used to identify patients who would benefit from treatment.
Dr. Philip D. Greenberg has been elected as the American Association for Cancer Research President-Elect for 2022-2023. He will work to harness advances in cancer research and translate them for patient benefit, with a focus on addressing disparities in minority engagement.
Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.
A new study found that omega-3 fatty acid supplementation can broadly improve immunotherapy and other anti-cancer drugs in the clinical setting. In mice, diets enriched with omega-3s blocked tumor growth when combined with immunotherapy or anti-inflammatory treatment, indicating possible synergistic anti-tumor activity.
Researchers at Penn Medicine have developed a new approach to alter immune cells for CAR T cell therapy in just 24 hours, cutting manufacturing time from nine to 14 days. This could make the therapy more cost-effective and accessible to more patients.
A new therapy combination of immunotherapy, chemotherapy and an anti-inflammatory drug may improve immune response in patients with muscle-invasive bladder cancer. The treatment activates cells to fight tumor growth, potentially leading to better outcomes for patients who don't respond to current treatments.
Researchers at Ben-Gurion University have developed a potential treatment combination for advanced head and neck cancer, which shows promise in pre-clinical models. The therapy involves blocking a specific signaling pathway and sensitizing tumors to immunotherapy, resulting in the disappearance of tumors.
The Experimental Biology (EB) 2022 meeting features live presentations and a moderated Q&A session on groundbreaking studies. The virtual press conference reveals potential treatments for Parkinson's disease, COVID-19 vaccine-associated side effects, and alleviating food allergies.
Researchers at Penn Medicine have discovered a new approach to treat solid cancers using CDH17CAR T cells, which selectively target and eliminate gastrointestinal (GI) solid tumors like gastric, pancreatic, and colorectal cancers in preclinical models. Unlike other immunotherapies, CDH17CAR T cells do not show toxicity to healthy tissues.
In an animal study, researchers created an implantable biotechnology called MASTER that produces and releases CAR-T cells for attacking cancerous tumors. This technology reduces the manufacturing time from weeks to hours, increasing efficiency and effectiveness.
Scientists at Albert Einstein College of Medicine have developed a novel therapeutic strategy that uses bacteria to deliver tetanus toxin into pancreatic tumor cells, inducing an immune response and killing the cancer. The treatment has shown promise in reducing cancer metastases by 87% and increasing mouse lifespan by 40%.
The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.
Dr. Steven A. Rosenberg's pioneering work on IL-2 and its use in treating metastatic melanoma and other cancers led to the FDA approval of first U.S.-born cancer immunotherapy. His subsequent research on CAR T-cell therapy has resulted in promising clinical results for various types of cancer.
Researchers found that adding atezolizumab to chemoradiation treatment was safe and demonstrated immune activation in women with node-positive, locally advanced cervical cancer. The study also showed increased peripheral blood T-cell receptor clonal expansion and tumor-associated T-cell clones.
Researchers have discovered an essential role of LCOR in enabling cancer cells to present tumour antigens, making them visible to the immune system. This approach increases the success of immunotherapy in triple-negative breast cancer, a subtype with low treatment response rates.
The ECOG-ACRIN Cancer Research Group has opened a new treatment arm in the NCI-MATCH trial for patients with DNA mismatch repair deficiency and LAG-3 expression. The trial is evaluating two immunotherapy combinations: relatlimab plus nivolumab and dabrafenib plus trametinib, both targeting BRAF mutations.
Scientists have developed a genetic screening platform to identify genes that enhance immune cells' persistence and ability to eradicate tumor cells. By combining these genes with existing CAR-T cell therapy, researchers were able to engineer T cells that are more effective at eliminating tumor cells.
Researchers developed a novel genetic barcode system to mark cancer cells with different gene modifications and image their characteristics. The Perturb-map platform identified specific genes controlling lung tumor growth, immune composition, and response to immunotherapy, offering new approaches for targeting anti-cancer drugs.
A new study reveals that intra-tumoral injections of a plant virus-based immunotherapy could lead to groundbreaking therapy for both canine and human inflammatory breast cancer patients. The treatment generated potent local and systemic anti-tumor immune responses, improving quality of life and survival in treated dogs.
Researchers have discovered a new treatment that blocks inflammation in pancreatic cancer, making it sensitive to chemotherapy and immunotherapy. The therapy more than doubled survival rates in mice with pancreatic cancer, providing promising results for future human trials.
Researchers found an association between a specific HLA-DPB1 gene variant and poor response to sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. The study suggests that genotyping the HLA-DPB1 gene could help predict patient responsiveness to SLIT.
Researchers developed a microneedle treatment that increased desensitization rates to peanut allergy in mice, outperforming existing immunotherapy methods. The novel approach achieved significant results using lower doses of allergen, offering new hope for millions suffering from peanut allergy.
A U-M study defines how a cytokine and fatty acid combination triggers ferroptosis, a type of cell death previously studied with synthetic molecules. This natural mechanism could make immunotherapy treatments more effective, particularly for cancers where the treatments currently work for only about 30% of patients.
Researchers found that patients with stage III melanoma who received immunotherapy alone had better rates of distant metastasis-free survival compared to those who underwent completion lymph node dissection. The study suggests that de-escalation of unnecessary therapies, such as CLND, may improve patient outcomes and reduce complications.
Researchers developed a novel scaffold to grow breast tumors with reduced immune variability, enabling more accurate immunotherapy drug testing. The new model replicates treatment-resistant breast cancer microenvironments and predicts patient responses to therapy.
A University of Cincinnati clinical trial showed promising results for patients with intermediate risk head and neck cancer when an immunotherapy drug, pembrolizumab, was added to standard treatment regimens. The study found improved one-year disease-free survival rates compared to historical controls.
Researchers at Lund University have developed a new precision medicine technology, TS-MAP, to identify and target cancer cell surface proteins. The method provides a direct analysis of all accessible cell surface tumour antigens in tumour tissue from patients.
A recent study found that women have a 34% higher risk of severe toxicity than men in cancer treatment, with higher risks for immunotherapy and targeted therapies. The analysis of over 20,000 patients from more than 200 clinical trials supports the idea that sex may independently modulate drug toxicity.
A recent study from Lund University found a previously unknown metabolic switch that regulates blood cell formation, enabling the directed production of natural killer cells for anti-cancer treatment. This discovery has significant implications for immunotherapy and cancer treatment.
Researchers have identified an antibody drug that significantly improves survival rates in pet dogs with advanced prostate cancer. By targeting regulatory T cells, the treatment may offer a new hope for patients with this devastating disease.
Two new treatments have been found to induce peanut allergy remission in children, with about half achieving remission and experiencing significant improvements in quality of life. The combination treatment and oral immunotherapy alone were both highly effective, providing substantial benefits for children's health and well-being.
Scientists at Technical University of Munich discovered a promising combination therapy for mesenchymal PDAC subtype, showing improved T-cell infiltration and cell cycle arrest when using nintedanib with trametinib. The treatment significantly improves the response of highly aggressive mesenchymal PDAC subtypes in mice.
Researchers found sublingual immunotherapy with house dust mite extract to be effective in reducing signs and symptoms of atopic dermatitis. The treatment, administered over 18 months, resulted in significant improvements in pruritus and lesions, with rare side effects.
Researchers have identified a germline biomarker signature that can predict serious side effects in up to 3 in 10 patients undergoing anti-PD1/PDL1 therapy. The findings represent an important step toward personalizing checkpoint therapy, potentially improving patient outcomes and reducing harm.
Researchers at Gladstone Institutes and UC San Francisco have developed a CRISPR activation method that allows them to activate genes in human immune cells, revealing key regulators of cytokine production. This breakthrough accelerates immunotherapy research and may lead to more powerful cancer treatments.
A Brazilian berry has been found to enhance the effectiveness of a popular cancer treatment by modifying the gut microbiome. Researchers discovered that castalagin, a polyphenol from the camu-camu fruit, improves immunotherapy response in mice with resistant cancers.
Researchers used a patient's own immune cells to target unique mutations in tumor DNA, leading to measurable tumor shrinkage in 67% of patients with metastatic breast cancer. The approach has potential as a personalized treatment for hormone receptor-positive breast cancers.
Researchers have discovered a new method to predict heart attacks by analyzing the gene expression of foamy macrophages, revealing a person's cardiovascular health. The study found that foamy cells can be both beneficial and detrimental depending on their behavior in individuals with certain conditions.
Researchers at Massachusetts General Hospital developed a safe and effective strategy to treat glioblastoma using short bursts of radiation therapy and nanoparticle-based immunotherapy. The combined approach suppresses tumor growth, induces anti-tumor immunity, and prolongs survival in animal models.
Researchers found that macrophages feed on lactic acid produced by cancer cells, paralyzing killer immune cells and weakening tumour immunity. This discovery highlights the need to curb lactic acid production in tumours to improve immunotherapy outcomes.
A clinical trial found that peanut oral immunotherapy desensitized most highly allergic children and induced remission in one-fifth. Younger children and those with lower levels of peanut-specific antibodies were more likely to achieve remission, with 71% of 1-year-olds experiencing remission.
A randomised controlled trial found that most young children treated with peanut immunotherapy achieved desensitisation after two and a half years of treatment, while one in five remained in remission. Younger children under one year old were more likely to achieve remission, suggesting early interventions may provide better outcomes.
A new bilateral tumor model was demonstrated to be useful for investigating the relationship between T-cell repertoire and cancer immunotherapy's therapeutic effects. The study found that T-cell profiles of both tumors were almost identical, indicating a similar anti-tumor response in a single mouse.
A team of scientists at the University of Missouri used small wearable sensors to gather data on how people with a traumatic hand amputation use a prosthesis versus a transplanted hand. The study found that hand transplant recipients exhibit a more balanced pattern of limb use, while prosthesis users rely heavily on their prosthetic hand.
The first-in-human trial of CAR-M cell therapy demonstrated that engineered macrophages can target and alter the solid tumor microenvironment, altering the composition of myeloid cells and T-cells. This innovative immunotherapy offers a promising new strategy in the fight against cancer.
A new study found that translocation renal cell carcinoma (tRCC) is characterized by genetic alterations except for the gene fusion from which it gets its name. The research suggests that tRCCs may be responsive to treatment with immune checkpoint inhibitors, providing a potential roadmap for clinical action.
Researchers at UCSF identify unique immune microenvironments in different types of cancer, paving the way for personalized immunotherapies. The study categorizes tumors into 12 groups based on their immune profile, suggesting that some cancers share similar characteristics despite being from different types.
The combination of relatlimab and nivolumab doubled progression-free survival benefit compared to nivolumab alone, with significant benefits across pre-specified subgroups. The treatment was associated with a lower risk of disease progression or death.
A high-fiber diet has been shown to improve the response of melanoma patients to immunotherapy by influencing the gut microbiome. Patients who consumed at least 20 grams of dietary fiber per day lived longer without their cancer progressing, compared to those who consumed less fiber.
Patients with sufficient fiber intake had improved progression-free survival and response to immunotherapy in melanoma. A high-fiber diet was associated with slower tumor growth and increased CD4+ T cells in pre-clinical models, supporting the potential benefits of dietary interventions on cancer treatment outcomes.
Scientists have identified the transcription factor Blimp1 as a new critical regulator of tumor-infiltrating regulatory T cells. Disrupting Blimp1 in these cells remodels the tumor microenvironment and augments the response to immunotherapy, promoting improved tumor control and anti-tumor immunity.
A new treatment combination of dasatinib, blinatumomab, and prednisone has shown promise in treating older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. The trial achieved a three-year DFS rate of 80 percent and an overall survival rate of 85 percent for enrolled patients.
A case study published in Nature Medicine reports a patient experiencing progressive neurological features resembling Parkinson's disease after CAR-T cell therapy, suggesting potential neurotoxicity. The study highlights the importance of monitoring for neurotoxicity in patients receiving BCMA-targeted CAR-T therapies.
Scientists from German Cancer Research Center show that blocking a cytokine slows down the immune system and exhausts T cells, leading to a more severe course of leukemia. The study suggests that a moderate activation of immune cells may be key to success in cancer immunotherapies.
Researchers at University of California San Diego found a way to boost innate immunity in liver cancer, making tumors highly responsive to immunotherapy. The combination of anti-PD-L1 antibody and polyIC molecule showed remarkable synergistic effects in liver tumor inhibition.
A recent review article describes a class of viruses known as oncolytic viruses, which have the remarkable ability to target and destroy cancer cells. Researchers are exploring these viruses for cancer therapy, with some showing promising results in stimulating an immune response against cancer.
Researchers found that second-generation antihistamines block histamine binding to HRH1, improving cytotoxic T cell activation and reducing resistance to immunotherapy. High plasma histamine levels in patients were correlated with worse responses to anti-PD-1 immunotherapy.
Gastric cancer is the sixth most common cancer worldwide, with 1.09 million new cases in 2020. Recent research offers hope for improved treatment options, making it a critical area of focus for medical oncologists like Dr. Mohamad Sonbol.
Researchers have developed an assay that uses specific immune-biomarkers to monitor patient survival chances and effectiveness of ovarian cancer treatments. The 'sFIS' assay will enable targeted therapy for each patient, improving treatment outcomes.
Researchers at Children's National Hospital have successfully developed a personalized T cell immunotherapy that targets and kills unique proteins in individual tumor cells. This approach, combining genetic sequencing and protein identification, offers a promising treatment option for children with hard-to-treat brain tumors.